DAPT After CABG: Recommendations Based on Clinical Scenario
DAPT Recommendations by Clinical Scenario
- The American College of Cardiology recommends dual antiplatelet therapy (DAPT) for 12 months in patients with acute coronary syndrome (ACS) after coronary artery bypass grafting (CABG) 1, 2
- In patients with stable coronary artery disease (SCAD) undergoing CABG, the European Heart Journal states that there is insufficient data to recommend routine DAPT 3, 4
- The American College of Cardiology suggests that DAPT (with clopidogrel initiated early postoperatively) for 12 months after CABG may be reasonable to improve vein graft patency in selected patients at low bleeding risk (Class IIb, Level B-NR recommendation) 2, 5
Bleeding Risk Considerations
- For patients at high bleeding risk, the European Heart Journal recommends considering a shorter duration of DAPT (6 months) 3, 4
- The American College of Cardiology states that in patients with increased bleeding risk (e.g., oral anticoagulation), the benefit/risk ratio may favor shorter-than-recommended duration of DAPT 2, 6
Specific Antiplatelet Recommendations
- The American College of Cardiology recommends a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) (Class I, Level B-NR) 2, 5
- The European Heart Journal considers clopidogrel as the default P2Y12 inhibitor when DAPT is indicated after CABG 3
- The European Heart Journal states that the use of ticagrelor or prasugrel is generally not recommended as part of triple antithrombotic therapy when oral anticoagulation is required 8
Common Pitfalls and Practical Considerations
- The American College of Cardiology recommends resuming P2Y12 inhibitor therapy postoperatively to complete the recommended duration of therapy in patients treated with DAPT after coronary stent implantation who subsequently undergo CABG 5
- The European Heart Journal recommends a proton pump inhibitor in patients at increased risk of gastrointestinal bleeding for the duration of combined antithrombotic therapy 8